Role of ChREBP–PPARα–FGF21 Axis in Metabolic Dysfunction of MASLD
Authors:
- Karina Mireya Palacios GirónKGKarina Mireya Palacios Girón
- Zamira Helena Hernandez NazaraZNZamira Helena Hernandez Nazara
- Montserrat Maldonado-GonzálezMMMontserrat Maldonado-González
- Erika Martínez-LópezEMErika Martínez-López
- Martha P. Sánchez MuñozMMMartha P. Sánchez Muñoz
- Carlos Alfredo Bautista LópezCLCarlos Alfredo Bautista López
- Ma. Soledad Aldana AguiñagaMAMa. Soledad Aldana Aguiñaga
- Jose Alfredo Dominguez-RosalesJDJose Alfredo Dominguez-Rosales
- Belinda Vargas-GuerreroBVBelinda Vargas-Guerrero
- Bertha Ruíz-MadrigalBRBertha Ruíz-Madrigal
Open Access
- 26 November 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (23) , 11425
Abstract
Metabolically Dysfunctional-Associated Steatotic Liver Disease (MASLD) affects both metabolically healthy obese (MHO) individuals and metabolically unhealthy lean (MUL) individuals. Key genes linked to liver dysfunction, such as MLXIPL, PPARA, and FGF21, are under-researched in humans. We aimed to evaluate the ChREBP–PPARα–FGF21 axis in relation to metabolic liver dysfunction in MHO and MUL individuals. Liver histopathology, biochemical data, anthropometric measurements, mRNA expression as analyzed by qPCR, and heatmap visualization were utilized to identify relationships among variables and discern gene expression patterns. ChREBP–PPARA–FGF21 genes were analyzed in liver, subcutaneous (SAT), and omental adipose tissue (OAT) biopsies from 55 subjects, including metabolically unhealthy obese (MUO), MHO, MUL, and metabolically healthy lean (MHL) subjects as controls. The MHL, MUL, MHO, and MUO groups showed a gradual increase in liver PPARα, with a downward trend in ChREBPβ levels in SAT (p < 0.05). Liver ChREBPβ positively correlated with insulin resistance and FGF21. Levels of OAT ChREBPβ showed a negative correlation with anthropometric measurements and serum insulin levels. These findings suggest coordinated regulation under metabolic stress. Increased FGF21 expression in the MUL and MUO groups may aid as a metabolic biomarker of impaired energy homeostasis and compensatory hepatic response.Keywords
Funding Information
- Programa de Incorporación y Permanencia de Posgrado (PROINPEP) y el Programa de apoyo a la mejora en las condiciones de producción de las personas integrantes del SNII y SNCA
- Programa Nacional de Becas del Consejo Nacional de Humanidades, Ciencias y Tecnologías (1041072)
This publication has 140 references indexed in Scilit:
- Beyond obesity: lean metabolic dysfunction-associated steatohepatitis from unveiling molecular pathogenesis to therapeutic advancementNaunyn-Schmiedeberg's Archives of Pharmacology, 2025
- A comparative genomic study across 396 liver biopsies provides deep insight into FGF21 mode of action as a therapeutic agent in metabolic dysfunction‐associated steatotic liver diseaseClinical and Translational Medicine, 2025
- World Medical Association Declaration of HelsinkiJAMA, 2025
- Fibroblast growth factor 21 is a hepatokine involved in MASLD progressionUnited European Gastroenterology Journal, 2024
- Phenotyping obesity: A focus on metabolically healthy obesity and metabolically unhealthy normal weightDiabetes/Metabolism Research and Reviews, 2023
- Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver DiseaseJAMA Network Open, 2019
- Disruption of mitochondrial fission in the liver protects mice from diet-induced obesity and metabolic deteriorationDiabetologia, 2015
- Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes MellitusJAMA, 2005
- Trends in management of gallbladder disorders in childrenPediatric Surgery International, 1997
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia, 1985